CL2012000800A1 - Uso de una cantidad de un anticuerpo antagonista de notch3 especifico para tratar leucemia de celulas t sensibles a inhibidores gama secretasa (gsi) que no responde a un antagonista de notch1 especifico, en un paciente con leucemia. - Google Patents

Uso de una cantidad de un anticuerpo antagonista de notch3 especifico para tratar leucemia de celulas t sensibles a inhibidores gama secretasa (gsi) que no responde a un antagonista de notch1 especifico, en un paciente con leucemia.

Info

Publication number
CL2012000800A1
CL2012000800A1 CL2012000800A CL2012000800A CL2012000800A1 CL 2012000800 A1 CL2012000800 A1 CL 2012000800A1 CL 2012000800 A CL2012000800 A CL 2012000800A CL 2012000800 A CL2012000800 A CL 2012000800A CL 2012000800 A1 CL2012000800 A1 CL 2012000800A1
Authority
CL
Chile
Prior art keywords
specific
leukemia
antagonist
gsi
treat
Prior art date
Application number
CL2012000800A
Other languages
English (en)
Spanish (es)
Inventor
Christian Siebel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2012000800A1 publication Critical patent/CL2012000800A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CL2012000800A 2009-09-30 2012-03-30 Uso de una cantidad de un anticuerpo antagonista de notch3 especifico para tratar leucemia de celulas t sensibles a inhibidores gama secretasa (gsi) que no responde a un antagonista de notch1 especifico, en un paciente con leucemia. CL2012000800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30

Publications (1)

Publication Number Publication Date
CL2012000800A1 true CL2012000800A1 (es) 2012-08-31

Family

ID=43127684

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000800A CL2012000800A1 (es) 2009-09-30 2012-03-30 Uso de una cantidad de un anticuerpo antagonista de notch3 especifico para tratar leucemia de celulas t sensibles a inhibidores gama secretasa (gsi) que no responde a un antagonista de notch1 especifico, en un paciente con leucemia.

Country Status (21)

Country Link
US (1) US9200071B2 (enExample)
EP (1) EP2483311B1 (enExample)
JP (3) JP6025563B2 (enExample)
KR (1) KR101782180B1 (enExample)
CN (1) CN102630229B (enExample)
AU (1) AU2010300747A1 (enExample)
BR (1) BR112012007252A2 (enExample)
CA (1) CA2775880A1 (enExample)
CL (1) CL2012000800A1 (enExample)
CO (1) CO6531430A2 (enExample)
CR (1) CR20120213A (enExample)
EC (1) ECSP12011858A (enExample)
ES (1) ES2580229T3 (enExample)
IL (1) IL218662A0 (enExample)
MA (1) MA33973B1 (enExample)
MX (1) MX342250B (enExample)
PE (1) PE20120998A1 (enExample)
PH (1) PH12012500574A1 (enExample)
RU (1) RU2012117619A (enExample)
WO (1) WO2011041336A2 (enExample)
ZA (1) ZA201201984B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2133796C1 (ru) * 1997-10-09 1999-07-27 ОАО "Томский электромеханический завод им.В.В.Вахрушева" Люк смотрового колодца
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CA2729306C (en) 2008-07-08 2015-08-18 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
RU2011151287A (ru) 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА
KR101580726B1 (ko) 2010-12-15 2015-12-29 와이어쓰 엘엘씨 항-노치1 항체
MX2015005810A (es) 2012-11-07 2015-09-23 Pfizer Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
US9879083B2 (en) 2012-12-19 2018-01-30 Aveo Pharmaceuticals, Inc. Anti-Notch3 antibodies
WO2014159242A1 (en) * 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
CN105246916A (zh) * 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
MX2015011386A (es) * 2013-03-15 2016-02-03 Oncomed Pharm Inc Metodo para tratar cancer pancreatico.
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
CA2936565C (en) 2014-02-12 2020-08-11 Genentech, Inc. Anti-jagged1 antibodies and methods of use
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
ES2931955T3 (es) 2016-04-29 2023-01-05 Aveo Pharmaceuticals Inc Anticuerpo anti-Notch3
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US20080181888A1 (en) 2004-12-31 2008-07-31 Ambrose Christine M Polypeptides That Bind Br3 and Uses Thereof
CL2007002989A1 (es) 2006-10-19 2008-05-16 Genentech Inc Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
RU2461569C2 (ru) 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
KR101568049B1 (ko) 2006-12-18 2015-11-11 제넨테크, 인크. 항-ｎｏｔｃｈ3 길항제 항체 및 ｎｏｔｃｈ3-관련 질환의 예방 및 치료에 있어서 그의 용도
US8088617B2 (en) * 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
EP2134356A2 (en) * 2007-03-05 2009-12-23 Board of Regents, The University of Texas System Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CA2729306C (en) * 2008-07-08 2015-08-18 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
RU2011151287A (ru) * 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА

Also Published As

Publication number Publication date
RU2012117619A (ru) 2013-11-10
ECSP12011858A (es) 2012-06-29
KR20120100952A (ko) 2012-09-12
EP2483311A2 (en) 2012-08-08
IL218662A0 (en) 2012-05-31
CN102630229A (zh) 2012-08-08
JP2017014219A (ja) 2017-01-19
JP2013506675A (ja) 2013-02-28
MA33973B1 (fr) 2013-02-01
JP2015145362A (ja) 2015-08-13
JP6025563B2 (ja) 2016-11-16
BR112012007252A2 (pt) 2020-08-11
US9200071B2 (en) 2015-12-01
US20120328608A1 (en) 2012-12-27
ES2580229T3 (es) 2016-08-22
PE20120998A1 (es) 2012-08-14
KR101782180B1 (ko) 2017-10-23
CR20120213A (es) 2012-07-09
EP2483311B1 (en) 2016-05-18
ZA201201984B (en) 2013-05-29
AU2010300747A1 (en) 2012-04-26
CN102630229B (zh) 2015-03-04
CA2775880A1 (en) 2011-04-07
PH12012500574A1 (en) 2012-10-22
WO2011041336A2 (en) 2011-04-07
HK1170505A1 (en) 2013-03-01
WO2011041336A3 (en) 2012-05-03
MX342250B (es) 2016-09-22
CO6531430A2 (es) 2012-09-28
MX2012003851A (es) 2012-05-08

Similar Documents

Publication Publication Date Title
CL2012000800A1 (es) Uso de una cantidad de un anticuerpo antagonista de notch3 especifico para tratar leucemia de celulas t sensibles a inhibidores gama secretasa (gsi) que no responde a un antagonista de notch1 especifico, en un paciente con leucemia.
CL2011000423A1 (es) Composicion que comprende un compuesto antagonista del receptor pd-1 y un agente potenciador; metodo para aumentar una respuesta de celulas t en un mamifero y su uso para tratar cancer.
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
BR112015003282A2 (pt) composições de cimento de geopolímero e métodos de uso
CL2012000429A1 (es) Uso de cepas de bifidobacterium longum para la elaboracion de una completa composicion que sirve para reducir los sintomas de alergias.
CR11029A (es) Anticuerpos en contra de erbb3 y usos de los mismos
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112016014966A2 (pt) Anticorpos e fragmentos anti-vista
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
CR20110421A (es) Agonistas y antagonistas del receptor de s1p, y métodos de uso de los mismos
CY1115848T1 (el) 1-αρυλο-3-αμινοαλκοξυ πυραζολες ως προσδετες σιγμα για την ενισχυση της αναλγητικης επιδρασης των οπιοειδων και την εξασθενηση της εξαρτησης απο αυτα
ECSP14019136A (es) Combinaciones farmacéuticas de un antagonista del receptor de angiotensina y un inhibidor de endopeptidasa neutra (nep)
MX2015009947A (es) Sistema aglomerante de geopolimero para uso en concretos mezcla de concreto refractario seco que contiene el sistema aglomerante y uso de la mezcla.
MX354230B (es) Composiciones marcadas inhibidoras de incrustacion y metodos para inhibir la incrustacion.
MX2009009552A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2008003122A1 (es) Uso de un anticuerpo anti-cd20 de tipo ii util para preparar un medicamento para tratar un cancer que expresa cd20 en combinacion con un inhibidor de proteasoma, composicion farmaceutica que contiene dicha combinacion y kit del mismo
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
NZ604510A (en) Dilutable biocidal compositions and methods of use
CL2012002904A1 (es) Combinación o composición farmacéutica que comprende un inhibidor de la señalización de células y/o de la angiogénesis y un inhibidor de la quinasa aurora (aki); kit faramcéutico que la comprende; su uso en el tratamiento de enfermedades oncológicas y fibróticas; y compuestos derivados de indol y pirimidina sustituidos.
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides